Navigation Links
Adeona and the Skirball Foundation Join Forces to Advance Multiple Sclerosis Research
Date:11/11/2011

ANN ARBOR, Mich., Nov. 11, 2011 /PRNewswire/ -- Adeona Pharmaceuticals, Inc. (NYSE Amex: AEN), a developer of innovative medicines for serious central nervous system diseases, announced that the Company's drug candidate, Trimesta™ (oral estriol), will be utilized in a new Phase II clinical trial to evaluate its potential therapeutic effect on cognitive dysfunction observed in female multiple sclerosis (MS) patients. The Skirball Foundation and Adeona have pledged to equally support this clinical trial led by Rhonda Voskuhl, M.D., Director, University of California, Los Angeles (UCLA) Multiple Sclerosis Program, Department of Neurology. The study, which focuses on cognition loss in MS patients, also received contributions from numerous supporters, such as the Sherak Family Fund, the Gustafson Fund, and the Diamont family.

"At some point, 50-65 percent of MS patients will develop problems due to cognitive loss, yet there remains no treatment to target this profound disability. Unfortunately, loss of cognition affects a person's ability to work and is the major reason MS patients stop or decrease their level of work," said Dr. Voskuhl, Principal Investigator. "We are therefore thrilled to begin this novel clinical trial of Trimesta in which the primary endpoint is improvement in cognition and the ultimate goal is to address an unmet need for these patients."

This new randomized, double-blind, placebo-controlled Phase II clinical trial is based on findings from a 10-patient, 22-month, single-agent, crossover clinical trial conducted by Dr. Voskuhl. The results from the crossover trial demonstrated a statistically significant 14% improvement from baseline in Paced Auditory Serial Addition Test (PASAT) cognitive testing scores (p = 0.04) in MS patients after six months of Trimesta therapy. PASAT is a routine cognitive test performed in patients with a wide variet
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Adeona Announces HartLab Expansion Into Microbiology Testing Services
2. Adeona Completes Equity Financing and Provides Alzheimers Disease Clinical Study Update
3. Adeona Announces Second Quarter 2010 Profitability and Achievements
4. Adeona Announces Five Scientific Publications on Role of Copper Toxicity and Zinc Deficiency in Alzheimers Disease and Cognitive Decline
5. Adeona CEO to Provide Keynote Address at the 2010 MichBio Expo & Conference Emerging Biosciences Showcase
6. Adeona to Hold Annual Shareholder Meeting
7. Adeona Announces Third Quarter 2010 Financial Results and Achievements
8. Adeona Acquires Access to Clinical Data Supporting Oral Zinc for Prevention of Infections in the Elderly
9. Adeona to Present at OneMedForum San Francisco 2011 Conference
10. Adeona to Host Investor Day on Zinc Deficiency in Alzheimers Disease
11. Adeona to Raise $4 Million in Registered Direct Offering
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/25/2014)... , July 25, 2014  The Chemistry, ... Tobago Ministry of Health approved the introduction of ... increases the cure rate from Hepatitis C, and ... genotype 1 virus. Telaprevir is available in ... INCIVO®. Photo - http://www2.prnewswire.com.br/imgs/pub/2014-07-25/original/2026.jpg   ...
(Date:7/25/2014)... , July 25, 2014  Solanbridge Group Inc ... acquired the majority interest in Buzznbrewz.com and the Letter ... replaced with a fully executed Purchase Agreement. ... stated "We are proud to have Mr. David ... decades of experience in the private sector and developed ...
(Date:7/25/2014)... Research and Markets has announced ... Market 2014-2018" report to their offering. ... Diagnostic Device An ophthalmic diagnostic device ... or deficiency in the human visual pathway. Ophthalmic devices ... presbyopia, cataracts, glaucoma, retinal disorders, conjunctivitis, and dry eyes. ...
Breaking Medicine Technology:The Hepatitis C virus is the main cause of liver transplant in the world 2The Hepatitis C virus is the main cause of liver transplant in the world 3Solanbridge Group Inc Announces Acquisition of Buzznbrewz.com 2Global Ophthalmic Diagnostic Devices Market 2014-2018: Key Vendors are Alcon, Carl Zeiss, Haag-Streit and Topcon 2
... of three-year,follow-up data showed that the CYPHER(R) Sirolimus-eluting ... bypass surgery in patients,with blockages in two or ... this week at the European Society of Cardiology,Congress ... analyses sought to assess the long-term impact of ...
... an Emerging Area ... of ... (OTC Bulletin,Board: LPTN), the category leader in therapeutic agents against ... cancer,and AMD with Lpathomab(TM), the company,s mouse monoclonal antibody against,LPA ...
Cached Medicine Technology:Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease 2Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease 3Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease 4Four Analyses of Three-Year Clinical Data Suggest CYPHER(R) Sirolimus-Eluting Coronary Stent May Provide Alternative to Surgery for Patients with Multivessel Disease 5Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 2Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process 3
(Date:7/26/2014)... According to the "Get Rid Tattoo ... a comprehensive guide that provides readers with safe and ... book also teaches them how to fade dark colored ... their own home for drastic results. , Vkool ... book includes step-by-step tutorials and product recommendations for treating ...
(Date:7/25/2014)... 26, 2014 PersonalInjurySolicitorsIreland, a legal ... to people who have suffered from a variety ... both their new company, and a website, ... new website explained, http://www.personalinjurysolicitorsireland.com/personal-injury-claims , the law ... of the company is always on the client, ...
(Date:7/25/2014)... (PRWEB) July 26, 2014 According ... Monitoring Market by Product (vibration monitoring, thermography, ultrasound ... signature analysis), Component, Application and Geography - Global ... the machine health monitoring market is expected to ... 2014 to 2020. , Browse 117 market data ...
(Date:7/25/2014)... 2014 As reported by the New Orleans ... Increasing (7/3), the state of Louisiana has recently seen ... even than cocaine. Officials believe the increase is due to ... “form” of marijuana. However, both doctors and police confirm that ... as to call it “poison,” doctors have acknowledged that the ...
(Date:7/25/2014)... Gerontological Society of America (GSA) the ... of aging has chosen Heather M. Young, ... Davis, as the 2014 recipient of the Doris ... honor, presented by GSA,s Health Sciences Section, is ... recognition of outstanding and sustained contribution to gerontological ...
Breaking Medicine News(10 mins):Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 2Health News:"Get Rid Tattoo Naturally" Book Review Exposes Jason Carter's Tattoo Removal Guide – Vkool.com 3Health News:PersonalInjurySolicitorsIreland.com Announces the Launch of their New Company and Website 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 2Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 3Health News:Machine Health Monitoring Market by Product, Component & Application Worth $2.50 Billion by 2020 - New Report by MarketsandMarkets 4Health News:Louisiana Recognizes Dangers of Synthetic Marijuana 2Health News:Young earns GSA's 2014 Doris Schwartz Gerontological Nursing Research Award 2
... BRUNSWICK, N.J., May 29 Johnson & Johnson,will ... & Diagnostics,businesses, as well as an update on ... 8:30 a.m. (Eastern Time) on Thursday,June 5, 2008, ... N.J., Donald Casey, Worldwide Chairman, Comprehensive Care ...
... program follows highly successful free antibiotic program ... date, GRAND RAPIDS, Mich., May 29 Supercenter ... in all 181 Meijer,pharmacies beginning June 1. The announcement ... for the Grand Rapids, Mich.-based retail chain., "As ...
... Three of the most terrifying words in,the English language ... and the fear factor rises even higher, since prostate cancer ... with early,detection is very curable., Give a gift of ... simple,blood test to screen for prostate cancer. If there is ...
... Physiology and Exercise Metabolism (Montana WPEM) will present a ... American College of Sports Medicine, showing that wildland ... supplement, Wellmune WGP, had far fewer 23 ... similar group of firefighters taking a placebo. , Montana ...
... Caraco Pharmaceutical,Laboratories, Ltd. (Amex: CPD ) posted record ... March 31, 2008 (Fiscal 2008), of $191.8 million,and $350.4 ... for the corresponding periods of Fiscal 2007. Net income ... quarter and Fiscal 2008,respectively, as compared to net income ...
... ... through in silence, COSTA MESA, Calif., May 29 ... see healthy hair, they now see,an increasing proportion of scalp. Agonizing over ... sometimes even hair,extensions, which can actually further damage already stressed-out hair., ...
Cached Medicine News:Health News:Meijer Pharmacies to Offer Free Pre-Natal Vitamins 2Health News:Give the Man in Your Life the Gift of Health 2Health News:Montana Center for Work Physiology and Exercise Metabolism presents firefighter health study 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 2Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 3Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 4Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 5Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 6Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 7Health News:Caraco Pharmaceutical Laboratories, Ltd. Reports Record Results for the Fourth Quarter and Fiscal Year 2008 8Health News:Hair Loss Is on the Rise, and Women Are Among the Hardest Hit 2
For the direct quantitative determination of low density lipoprotein cholesterol (LDL-C) in human serum or plasma. For in vitro diagnostic use only....
Storage temperature: 2 - 8C, linearity: 0 - 25 mg/dL, expected value: male: 3.5 - 7.0 mg/dL and female: 2.5 - 6.0 mg/dL. Available with calibrator and number of test 500....
Storage temperature: 15 - 30C, linearity: 0 - 20 mg/dL, expected value: male: 3.0 - 7.0 mg/dL and female: 2.2 - 6.2 mg/dL. Available with calibrator and number of tests 125....
The assay kit is for determination of uric acid in serum or urine. Wavelength: 600 nm. Linear range: up to 80 mg/dL....
Medicine Products: